
INSIGHT

PHARMA SERVICES
SECTOR SNAPSHOT



JUNE 2017

BOURNE PARTNERS

CMO - Transaction Comps

BOURNE PARTNERS

		СМО	Transaction Comps						
Announced Date	Target	Target Description	Buyer	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LTM EBITDA
May-17	Patheon	Provides outsourced pharmaceutical development and manufacturing services	Thermo Fisher	USA	\$7,110.9	\$1,918.2	\$358.1	3.7x	19.9x
Dec-16	CMC Biologics	Provides contract process development and biopharmaceuticals manufacturing services	Asahi Glass Co.	Denmark	514.3	NA	NA	NA	NA
Dec-16	Capsugel	Develops dosage forms and solutions for the healthcare industry around the world	^y Catalent	USA	5,500.0	1,000.0	344.0	5.5x	16.0x
Nov-16	Accucaps Industries	Engages in the contract manufacturing of pharmaceutical and nutritional products, primarily utilizing its soft gel technology	Cambrex	Canada	75.0	NA	NA	NA	NA
Sep-16	PharmaCore	Specializes in developing, manufacturing, and scaling up APIs fo clinical phase projects	r Piramal	USA	25.0	17.0	45.4	2.7x	12.9x
Aug-16	Ash Stevens	Develops and manufactures drug substances and APIs	Fosun Pharma	USA	53.0	18.3	NA	2.9x	NA
Jul-16	Gland Pharma	Manufactures small volume parenterals including vials, ampoules, pre-filled syringes, and lyophilized vials	Thermo Fisher Scientific	India	1,551.0	188.2	NA	8.2x	NA
May-16	Euticals	Manufactures and sells APIs, customs synthesis, and fine chemical products	Thermo Fisher Scientific	Italy	353.1	243.1	26.8	1.5x	13.2x
Jan-15	Coldstream Laboratories	Provides integrated analytical, formulation development, and pharmaceutical manufacturing services	Piramal	USA	28.9	13.1	NA	2.2x	NA
Sep-14	Shasun Pharmaceuticals	Manufactures and sells APIs, intermediates, and formulations to the pharmaceutical industry, primarily in India	Strides Arcolab Ltd.	India	295.1	213.0	26.3	1.4x	11.2x
Sep-14	Sigma-Aldrich	Develops, manufactures, purchases, distributes various chemicals, biochemicals, and equipment products worldwide	Merck	USA	16,495.2	2,738.0	834.0	6.0x	19.8x
Mar-14	Cedarburg Hauser Pharmaceuticals	Specializes in the development and manufacture of technically complex small molecule APIs	Albany Molecular Research, Inc.	USA	41.0	16.2	5.5	2.5x	7.5x
Notes:									
NM - Not Mear				Mediar		\$215.7	\$194.7	3.3x	14.6x
NA - Not Availa Source: Capitall				Mear	,	1,918.2	193.6 358.1	4.1x 8.2x	15.5x 19.9x
*Transaction no				High Low		1,918.2	26.8	8.2x 1.5x	19.9x 12.9x

CRO - Transaction Comps

Bourne Partners

		CRO 1	ransaction Comps						
Announced Date	Target	Target Description	Buyer	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LTM EBITDA
Jan-17	*J-STAR Research	Custom synthesis/contract research organization	Porton USA	USA	\$26.0	NA	NA	NA	NA
Sep-16	Agilux Laboratories	Services supporting discovery, pre-clinical, and clinical services; provides a range of drug metabolism and pharmacokinetic Services	Charles River Laboratories International	USA	64.0	NA	NA	NA	NA
Jun-16	Adesis	Specializes in organic synthesis, custom synthesis, and full time equivalents services	Universal Display Corporation	USA	36.0	10.0	NA	3.6x	NA
Jan-16	WIL Research Laboratories	Provides safety assessment, and contract development and manufacturing services	Charles River Laboratories International	USA	NA	218.2	45.4	2.7x	12.9x
Jun-15	Hangzhou Neptunus Bioengineering Co.	Researches, develops, and supplies oral solutions, tablets, capsules, and soft capsules	Shenzhen Neptunus Group Co.	China	32.9	8.4	NA	3.9x	NA
Jul-14	Penn Pharmaceutical Services	Offers pharmaceutical drug development, clinical trial supply, and pharmaceutical manufacturing services	Packaging Coordinators	United Kingdom	215.7	51.0	NA	4.2x	NA
Mar-14	BioFocus DPI	Develops gene-to-candidate drug discovery products and provides services	Charles River Laboratories	United Kingdom	186.5	87.7	15.5	2.1x	12.0x
Jan-14	СееТох	Focuses on in vitro toxicity screening of new drug candidates, chemicals, cosmetics, and consumer products	Apredica, LLC (nka:Cyprotex US, LLC)	USA	6.1	3.8	NA	1.6x	NA
Notes:									
NM - Not Mean	ningful			Mediar	\$36.0	\$30.5	\$30.5	3.2x	12.5x
NA - Not Availa				Mear		63.2	30.5	3.0x	12.5x
Source: Capitall				High		218.2	45.4	4.2x	12.9x
*Transaction no	ot yet closed			Lov	6.1	3.8	15.5	1.6x	12.0x

Distribution - Transaction Comps

BOURNE PARTNERS

		Pharma Distri	ibution Transaction	n Comps					
Announced Date	Target	Target Description	Buyer	Geographic Location	Enterprise Value	LTM Revenue	LTM EBITDA	EV / LTM Revenue	EV / LTM EBITDA
Mar-17	Pelion S.A.	Engages in the trade of pharmaceuticals, cosmetics, and parapharmaceuticals operating through wholesale, retail, services, and other segments in Poland	Korporacja Inwestycyjna Polskiej Farmacji Sp. z o.o.	Poland	\$323.4	\$2,399.5	\$31.5	0.1x	10.3x
Oct-16	Cyprotex plc	Provides in vitro and in silico absorption, distribution, metabolism, excretion, and toxicity/ pharmacokinetic (ADMET and PK) information services	Evotec AG	United Kingdom	54.9	21.3	5.4	2.6x	10.2x
Aug-16	Anda, Inc.	Distributes generic, branded, specialty, and over-the-counter pharmaceutical products	Teva Pharmaceutical Industries Limited	USA	500.0	NA	NA	NA	NA
Jul-16	Pharmapar Inc.	Distributes generics drugs for privately insured individuals offering a range of medication types	AlliancePharma Inc. (nka:KDA Group Inc.)	Canada	11.1	17.3	NA	0.6x	NA
May-16	Symmetry Surgical Inc.	Manufactures and distributes medical devices worldwide offering	RoundTable Healthcare Partners IV, L.P	USA	142.2	84.1	9.1	1.7x	15.6x
Mar-16	Rexall Pharma Plus Ltd.	Operates a network of retail pharmacy stores in Canada offering prescription centers that focus primarily on prescription and ove the-counter products		Canada	2,154.3	2,000.0	200.0	1.1x	11.1x
Apr-15	Idis Group Holdings Ltd	Provides access to unlicensed pharmaceutical products internationally	Clinigen Group Plc	United Kingdom	341.4	274.5	19.0	1.2x	18.0x
Feb-15	BioRx, LLC	Distributes specialty pharmaceuticals and medical supplies, and provides infusion services in the United States	Diplomat Pharmacy, Inc.	USA	347.8	227.0	23.0	1.5x	15.1x
Jan-15	Norchem Ltd.	Distributes and markets pharmaceuticals	Lexon (UK) Limited	United Kingdom	34.9	37.9	NA	0.9x	NA
Mar-14	Central Healthcare Pty Ltd	Distributes pharmaceutical products serving hospitals and retail pharmacies in Victoria	Sigma Pharmaceuticals Limited (nka:Sigma Healthcare Limited)	Australia	42.5	184.5	NA	0.2x	NA
Feb-14	Celesio AG	Provides logistics and services to the pharmaceutical and healthcare sectors worldwide	Celesio Holdings Deutschland GmbH & Co. KGaA	Germany	6,272.5	25,505.1	571.9	0.2x	11.0x
Votes:									
VM - Not Mean	ningful			Mediar	\$323.4	\$179.3	\$19.0	1.2x	11.1x
NA - Not Availa	ble			Mear	503.9	799.5	53.0	1.2x	13.0x
Source: Capitall				High		2,399.5	200.0	2.6x	18.0x
Transaction no	ot yet closed			Low	11.1	17.3	5.4	0.1x	10.2x

Source: S&P Capital IQ, May 25, 2017

Trading Comps - By Sector

BOURNE PARTNERS

								Comp	_									
USD in millions, except for per-share amour	nts					LT	м	NTM Fo	recast	NTM YoY	Growth	Margin	Anlyeie		Enterprise	Value/		Deb
Company	Ticker	Share Price	Equity Value	Net Debt (Cash)	Enterprise Value	Sales	EBITDA	Sales	EBITDA	Sales	EBITDA	Gross Profit	EBITDA	Sales	EBITDA	NTM Sales	NTM EBITDA	EBITE
Albany Molecular Research, Inc.	NASDAQ:AMRI	\$18.60	\$775.2	\$606.3	\$1,381.4	\$628.7	\$71.8	\$735.7	\$140.2	17.0%	95.3%	23.5%	11.4%	2.2 x	19.2 x	1.9 x	9.9 x	8
Bachem Holding AG	SWX:BANB	121.71	1,649.1	35.7	1,684.8	232.8	63.7	273.4	78.8	17.5%	23.7%	32.7%	27.4%	7.2 x	26.4 x	6.2 x	21.4 x	
alchem Corporation	NasdaqGS:BCPC	79.35	2,528.6	231.9	2,760.5	555.8	137.2	573.8	150.4	3.2%	9.6%	32.4%	24.7%	5.0 x	20.1 x	4.8 x	18.4 x	
Cambrex Corporation	NYSE:CBM	53.50	1,742.5	(99.2)	1,643.3	500.6	161.8	550.6	172.3	10.0%	6.5%	42.3%	32.3%	3.3 x	10.2 x	3.0 x	9.5 x	
Catalent, Inc.	NYSE:CTLT	35.83	4,476.9	1,780.2	6,257.1	1,990.7	395.3	2,095.4	466.9	5.3%	18.1%	31.5%	19.9%	3.1 x	15.8 x	3.0 x	13.4 x	
lubilant Life Sciences Limited	BSE:530019	11.00	1,752.2	504.7	2,256.9	904.6	207.1	1,050.8	252.6	16.2%	21.9%	60.2%	22.9%	2.5 x	10.9 x	2.1 x	8.9 x	
Koninklijke DSM N.V.	ENXTAM:DSM	73.93	12,831.3	2,033.8	14,865.1	8,731.8	1,208.3	9,551.6	1,550.1	9.4%	28.3%	35.6%	13.8%	1.7 x	12.3 x	1.6 x	9.6 x	
_onza Group Ltd	SWX:LONN	207.41	15,418.9	1,605.7	17,024.6	4,067.8	853.5	5,227.4	1,293.2	28.5%	51.5%	34.5%	21.0%	4.2 x	19.9 x	3.3 x	13.2 x	
Patheon N.V.	NYSE:PTHN	34.60	5,021.7	2,017.2	7,038.9	1,918.2	359.6	2,056.7	459.2	7.2%	27.7%	30.2%	18.7%	3.7 x	19.6 x	3.4 x	15.3 x	
		288.32	1.131.4	58.8	1.190.2	706.6	88.4	794.7	123.2	12.5%	39.3%	15.2%	12.5%	1.7 x	13.5 x	1.5 x	9.7 x	
All estimates from Capital IQ Debt calculations only included for entities v	SWX:SFZN vith debt	200.32									Median Mean Min Max	0.3% 0.3% 0.2% 0.6%	20.4% 20.5% 11.4% 32.3%	3.2 x 3.5 x 1.7 x 7.2 x	17.5 x 16.8 x 10.2 x 26.4 x	3.0 x 3.1 x 1.5 x 6.2 x	11.5 x 12.9 x 8.9 x 21.4 x	
* All estimates from Capital IQ Debt calculations only included for entities v NM - not meaningful USD in millions, except for per-share amounts.	vith debt	200.02				CRO		Comp			Mean Min Max	0.3% 0.2% 0.6%	20.5% 11.4% 32.3%	3.5 x 1.7 x	16.8 x 10.2 x 26.4 x	3.1 x 1.5 x 6.2 x	12.9 x 8.9 x	
All estimates from Capital IQ Debt calculations only included for entities v IM - not meaningful	vith debt		Fauity	Not Dobt	Enternrise	CRO LT		Comps		NTM YoY	Mean Min Max	0.3% 0.2% 0.6% Margin	20.5% 11.4% 32.3%	3.5 x 1.7 x	16.8 x 10.2 x	3.1 x 1.5 x 6.2 x	12.9 x 8.9 x 21.4 x	De
All estimates from Capital IQ Debt calculations only included for entities v IM - not meaningful JSD in millions, except for per-share amounts	vith debt	Share Price	Equity Value	Net Debt (Cash)	Enterprise Value					NTM YoY	Mean Min Max	0.3% 0.2% 0.6%	20.5% 11.4% 32.3%	3.5 x 1.7 x	16.8 x 10.2 x 26.4 x	3.1 x 1.5 x 6.2 x	12.9 x 8.9 x	De EBIT
All estimates from Capital IQ Debt calculations only included for entities v M - not meaningful JSD in millions, except for per-share amount Company	vith debt orts Ticker	Share Price	Value	(Cash)	Value	LT Sales	M EBITDA	NTM Fo	recast EBITDA	Sales	Mean Min Max Growth	0.3% 0.2% 0.6% Margin Gross Profit	20.5% 11.4% 32.3% Anlysis	3.5 x 1.7 x 7.2 x	16.8 x 10.2 x 26.4 x Enterprise	3.1 x 1.5 x 6.2 x	12.9 x 8.9 x 21.4 x	
All estimates from Capital IQ bebt calculations only included for entities v MI - not meaningful JSD in millions, except for per-share amount Company Charles River Laboratories International, Inc.	ots Ticker NYSE:CRL	Share Price \$92.67	Value \$4,414.7	(Cash) \$1,062.0	\$5,476.7	Sales \$1,772.3	EBITDA \$424.0	NTM Fo	EBITDA \$462.0	Sales 5.0%	Mean Min Max Growth EBITDA 9.0%	0.3% 0.2% 0.6% Margin Gross Profit	20.5% 11.4% 32.3% Anlysis EBITDA	3.5 x 1.7 x 7.2 x Sales	16.8 x 10.2 x 26.4 x Enterprise EBITDA	3.1 x 1.5 x 6.2 x Walue/ NTM Sales	12.9 x 8.9 x 21.4 x	
All estimates from Capital IQ bebt calculations only included for entities v IM - not meaningful ISD in millions, except for per-share amount Company Charles River Laboratories International, Inc. CON Public Limited Company	vith debt Ticker NYSE:CRL NasdaqGS:ICLR	Share Price \$92.67	\$4,414.7 4,847.6	(Cash) \$1,062.0 29.6	\$5,476.7 4,877.2	\$1,772.3 1,697.9	M EBITDA \$424.0 388.4	NTM Fo Sales \$1,861.1 1,737.3	### ##################################	5.0% 2.3%	Mean Min Max Growth EBITDA 9.0% 3.5%	0.3% 0.2% 0.6% Margin Gross Profit 39.1% 42.1%	20.5% 11.4% 32.3% Anlysis EBITDA 23.9% 22.9%	3.5 x 1.7 x 7.2 x Sales 3.1 x 2.9 x	16.8 x 10.2 x 26.4 x Enterprise EBITDA 12.9 x 12.6 x	3.1 x 1.5 x 6.2 x Value/ NTM Sales 2.9 x 2.8 x	12.9 x 8.9 x 21.4 x NTM EBITDA 11.9 x 12.1 x	
All estimates from Capital IQ Debt calculations only included for entities v IM - not meaningful JSD in millions, except for per-share amount Company Charles River Laboratories International, Inc. CON Public Limited Company NC Research Holdings, Inc.	ticker NYSE:CRL NasdaqGS:ICLR NASDAQ:INCR	Share Price \$92.67 90.14 56.30	\$4,414.7 4,847.6 3,046.1	\$1,062.0 29.6 322.7	\$5,476.7 4,877.2 3,368.7	\$1,772.3 1,697.9 1,033.4	EBITDA \$424.0 388.4 230.4	NTM Fo Sales \$1,861.1 1,737.3 1,092.8	### ##################################	5.0% 2.3% 5.7%	Mean Min Max Growth EBITDA 9.0% 3.5% 16.0%	0.3% 0.2% 0.6% Margin Gross Profit 39.1% 42.1% 39.1%	20.5% 11.4% 32.3% Anlysis EBITDA 23.9% 22.9% 22.3%	3.5 x 1.7 x 7.2 x Sales 3.1 x 2.9 x 3.3 x	Enterprise EBITDA 12.9 x 12.6 x 14.6 x	3.1 x 1.5 x 6.2 x Value/ NTM Sales 2.9 x 2.8 x 3.1 x	12.9 x 8.9 x 21.4 x NTM EBITDA 11.9 x 12.1 x 12.6 x	EBI
All estimates from Capital IQ Debt calculations only included for entities v IM - not meaningful USD in millions, except for per-share amount Company Charles River Laboratories International, Inc. CON Public Limited Company NC Research Holdings, Inc. Medpace Holdings, Inc.	Ticker NYSE:CRL NasdaqGS:ICLR NASDAQ:INCR NasdaqGS:MEDP	\$92.67 90.14 56.30 27.05	\$4,414.7 4,847.6 3,046.1 1,102.1	\$1,062.0 29.6 322.7 159.4	\$5,476.7 4,877.2 3,368.7 1,261.4	\$1,772.3 1,697.9 1,033.4 376.6	EBITDA \$424.0 388.4 230.4 110.8	NTM Fo Sales \$1,861.1 1,737.3 1,092.8 382.7	### ##################################	5.0% 2.3% 5.7% 1.6%	Mean Min Max Growth EBITDA 9.0% 3.5% 16.0% (3.9%)	0.3% 0.2% 0.6% Margin Gross Profit 39.1% 42.1% 39.1% 46.2%	20.5% 11.4% 32.3% Anlysis EBITDA 23.9% 22.9% 22.3% 29.4%	3.5 x 1.7 x 7.2 x Sales 3.1 x 2.9 x 3.3 x 3.3 x	Enterprise EBITDA 12.9 x 12.6 x 14.6 x 11.4 x	3.1 x 1.5 x 6.2 x	12.9 x 8.9 x 21.4 x NTM EBITDA 11.9 x 12.1 x 12.6 x 11.8 x	EBI
All estimates from Capital IQ Debt calculations only included for entities v IM - not meaningful USD in millions, except for per-share amount Company Charles River Laboratories International, Inc. CON Public Limited Company NC Research Holdings, Inc.	ticker NYSE:CRL NasdaqGS:ICLR NASDAQ:INCR	Share Price \$92.67 90.14 56.30	\$4,414.7 4,847.6 3,046.1	\$1,062.0 29.6 322.7	\$5,476.7 4,877.2 3,368.7	\$1,772.3 1,697.9 1,033.4	EBITDA \$424.0 388.4 230.4	NTM Fo Sales \$1,861.1 1,737.3 1,092.8	### ##################################	5.0% 2.3% 5.7%	Mean Min Max Growth EBITDA 9.0% 3.5% 16.0%	0.3% 0.2% 0.6% Margin Gross Profit 39.1% 42.1% 39.1%	20.5% 11.4% 32.3% Anlysis EBITDA 23.9% 22.9% 22.3%	3.5 x 1.7 x 7.2 x Sales 3.1 x 2.9 x 3.3 x	Enterprise EBITDA 12.9 x 12.6 x 14.6 x	3.1 x 1.5 x 6.2 x Value/ NTM Sales 2.9 x 2.8 x 3.1 x	12.9 x 8.9 x 21.4 x NTM EBITDA 11.9 x 12.1 x 12.6 x	EBI
All estimates from Capital IQ lebt calculations only included for entities vill in not meaningful size in millions, except for per-share amount in millions, exc	Ticker NYSE:CRL NasdaqGS:ICLR NASDAQ:INCR NasdaqGS:MEDP NasdaqGS:PRXL	\$92.67 90.14 56.30 27.05 79.65	\$4,414.7 4,847.6 3,046.1 1,102.1 4,043.2	\$1,062.0 29.6 322.7 159.4 415.6	\$5,476.7 4,877.2 3,368.7 1,261.4 4,458.8	\$1,772.3 1,697.9 1,033.4 376.6 2,097.0	**EBITDA** \$424.0 388.4 230.4 110.8 342.8	\$1,861.1 1,737.3 1,092.8 382.7 2,178.0	### EBITDA \$462.0 401.9 267.2 106.5 390.7	5.0% 2.3% 5.7% 1.6% 3.9%	Growth EBITDA 9.0% 3.5% 16.0% (3.9%) 14.0%	0.3% 0.2% 0.6% Margin Gross Profit 39.1% 42.1% 39.1% 46.2% 34.4%	20.5% 11.4% 32.3% Anlysis EBITDA 23.9% 22.9% 22.3% 29.4% 16.3%	3.5 x 1.7 x 7.2 x Sales 3.1 x 2.9 x 3.3 x 3.3 x 2.1 x	Enterprise EBITDA 12.9 x 12.6 x 14.6 x 11.4 x 13.0 x	3.1 x 1.5 x 6.2 x e Value/ NTM Sales 2.9 x 2.8 x 3.1 x 3.3 x 2.0 x	12.9 x 8.9 x 21.4 x 21.	EBI
All estimates from Capital IQ Debt calculations only included for entities v IM - not meaningful JSD in millions, except for per-share amount Company Charles River Laboratories International, Inc. CON Public Limited Company NC Research Holdings, Inc. Medpace Holdings, Inc. PAREXEL International Corporation	Ticker NYSE:CRL NasdaqGS:ICLR NASDAQ:INCR NasdaqGS:MEDP NasdaqGS:PRXL NasdaqGS:PRAH	\$92.67 90.14 56.30 27.05 79.65 72.08	\$4,414.7 4,847.6 3,046.1 1,102.1 4,043.2 4,503.0	\$1,062.0 29.6 322.7 159.4 415.6 696.9	\$5,476.7 4,877.2 3,368.7 1,261.4 4,458.8 5,199.9	\$1,772.3 1,697.9 1,033.4 376.6 2,097.0 1,634.8	### EBITDA \$424.0 \$88.4 230.4 110.8 342.8 262.6	\$1,861.1 1,737.3 1,092.8 382.7 2,178.0 1,884.4	\$462.0 401.9 267.2 106.5 390.7 364.9	5.0% 2.3% 5.7% 1.6% 3.9% 15.3%	Mean Min Max Growth EBITDA 9.0% (3.5% (3.9%) 14.0% (3.9.0) 62.0%	0.3% 0.2% 0.6% Margin Gross Profit 39.1% 42.1% 39.1% 46.2% 34.4% 34.1% 40.7%	20.5% 11.4% 32.3% Anlysis EBITDA 23.9% 22.9% 22.3% 16.3% 16.1% 20.7%	3.5 x 1.7 x 7.2 x Sales Sales 3.1 x 2.9 x 3.3 x 2.1 x 3.2 x 4.2 x	Enterprise Enterprise Enterprise EBITDA 12.9 x 12.6 x 14.6 x 11.4 x 13.0 x 19.8 x 20.5 x	3.1 x 1.5 x 6.2 x e Value/ NTM Sales 2.9 x 2.8 x 3.1 x 3.3 x 2.0 x 2.8 x 3.2 x	12.9 x 8.9 x 21.4 x NTM EBITDA 11.9 x 12.1 x 12.6 x 11.4 x 14.2 x 12.6 x	EBI
All estimates from Capital IQ Debt calculations only included for entities of MM - not meaningful JSD in millions, except for per-share amount Company Charles River Laboratories International, Inc. CON Public Limited Company NC Research Holdings, Inc. Adedpace Holdings, Inc. PAREXEL International Corporation PRA Health Sciences, Inc. Quintiles IMS Holdings, Inc.	Ticker NYSE:CRL NasdaqGS:ICLR NASDAQ:INCR NasdaqGS:MEDP NasdaqGS:PRXL NasdaqGS:PRAH	\$92.67 90.14 56.30 27.05 79.65 72.08	\$4,414.7 4,847.6 3,046.1 1,102.1 4,043.2 4,503.0	\$1,062.0 29.6 322.7 159.4 415.6 696.9	\$5,476.7 4,877.2 3,368.7 1,261.4 4,458.8 5,199.9	\$1,772.3 1,697.9 1,033.4 376.6 2,097.0 1,634.8	### EBITDA \$424.0 \$88.4 230.4 110.8 342.8 262.6	\$1,861.1 1,737.3 1,092.8 382.7 2,178.0 1,884.4	\$462.0 401.9 267.2 106.5 390.7 364.9	5.0% 2.3% 5.7% 1.6% 3.9% 15.3%	Mean Min Max Growth EBITDA 9.0% 3.55% 16.0% (3.9%) 14.0% 39.0%	0.3% 0.2% 0.6% Margin Gross Profit 39.1% 42.1% 39.19 46.2% 34.4% 34.1%	20.5% 11.4% 32.3% Anlysis EBITDA 23.9% 22.3% 22.3% 29.4% 16.3% 16.1%	3.5 x 1.7 x 7.2 x Sales Sales 3.1 x 2.9 x 3.3 x 2.1 x 3.2 x 3.2 x	Enterprise EBITDA 12.9 x 14.6 x 11.4 x 20.5 x 11.4 x 13.0 x 19.8 x 20.5 x	3.1 x 1.5 x 6.2 x e Value/ NTM Sales 2.9 x 2.8 x 3.1 x 3.3 x 2.0 x 2.8 x	12.9 x 8.9 x 21.4 x NTM EBITDA 11.9 x 12.1 x 12.6 x 11.8 x 11.4 x 14.2 x	EBI
All estimates from Capital IQ Debt calculations only included for entities of the control of the	Ticker NYSE:CRL NasdaqGS:ICLR NASDAQ:INCR NasdaqGS:MEDP NasdaqGS:PRXL NasdaqGS:PRXL NASDAQ:NSE:Q	\$92.67 90.14 56.30 27.05 79.65 72.08	\$4,414.7 4,847.6 3,046.1 1,102.1 4,043.2 4,503.0	\$1,062.0 29.6 322.7 159.4 415.6 696.9	\$5,476.7 4,877.2 3,368.7 1,261.4 4,458.8 5,199.9	\$1,772.3 1,697.9 1,033.4 376.6 2,097.0 1,634.8	### EBITDA \$424.0 \$88.4 230.4 110.8 342.8 262.6	\$1,861.1 1,737.3 1,092.8 382.7 2,178.0 1,884.4	\$462.0 401.9 267.2 106.5 390.7 364.9	5.0% 2.3% 5.7% 1.6% 3.9% 15.3%	Mean Min Max Growth EBITDA 9.0% 3.5% 16.0% (3.9%) 62.0% Median	0.3% 0.2% 0.6% Margin Gross Profit 39.1% 42.1% 39.1% 46.2% 34.4% 34.1%	20.5% 11.4% 32.3% Anlysis EBITDA 23.9% 22.9% 29.4% 16.3% 16.19 20.7%	3.5 x 1.7 x 7.2 x 3.1 x 2.9 x 3.3 x 3.2 x 4.2 x 3.2 x 5.2 x 6.2 x	Enterprise EBITDA 12.9 x 14.6 x 11.4 x 20.5 x 11.4 x 13.0 x 19.8 x 20.5 x	3.1 x 1.5 x 6.2 x 8 Value/ NTM Sales 2.9 x 2.8 x 3.1 x 3.3 x 2.0 x 2.8 x 3.2 x 2.9 x	12.9 x 8.9 x 21.4 x 21.6 x 21.6 x 21.6 x 21.6 x 21.6 x 21.6 x 21.1 x 21.6 x 21.1 x 21.6 x 21.1 x 21.6 x 21.1 x 21.	EBI

1100: 11:	Distribution Trading Comps in millions, except for per-share amounts																	
USD In millions, except for per-snare a					LTM		NTM Forecast		NTM YoY Growth		Margin Anlysis			Enterprise Value/			Debt/	
Company	Ticker	Share Price	Equity Value	Net Debt (Cash)	Enterprise Value	Sales	EBITDA	Sales	EBITDA	Sales	EBITDA	Gross Profit	EBITDA	Sales	EBITDA	NTM Sales	NTM EBITDA	EBITDA
AmerisourceBergen Corporation	NYSE:ABC	\$91.29	\$19,934.1	\$2,051.0	\$21,985.1	\$149,759.0	\$2,340.8	\$161,754.1	\$2,343.8	8.0%	0.1%	2.9%	1.6%	0.1 x	9.4 x	0.1 x	9.4 x	1.9
Cardinal Health, Inc.	NYSE:CAH	73.36	23,171.9	4,093.0	27,264.9	128,394.0	3,099.0	137,120.5	3,225.1	6.8%	4.1%	5.1%	2.4%	0.2 x	8.8 x	0.2 x	8.5 x	1.8
Celesio AG	DB:CLS1	29.00	5,892.4	1,608.7	7,501.1	23,737.2	488.4	0.0	0.0	(100.0%)	(100.0%)	10.1%	2.1%	0.3 x	15.4 x	NM	NM	4.1
McKesson Corporation	NYSE:MCK	162.17	34,202.1	5,762.0	39,964.1	198,533.0	4,354.0	205,584.3	4,480.0	3.6%	2.9%	5.7%	2.2%	0.2 x	9.2 x	0.2 x	8.9 x	2.0
Owens & Minor, Inc.	NYSE:OMI	32.34	1,979.3	437.0	2,416.2	9,596.2	254.5	9,772.0	267.1	1.8%	4.9%	12.2%	2.7%	0.3 x	9.5 x	0.2 x	9.0 x	2.2
UDG Healthcare plc	LSE:UDG	10.52	2,611.3	(71.5)	2,539.8	1,049.3	137.0	1,195.4	161.8	13.9%	18.1%	30.2%	13.1%	2.4 x	18.5 x	2.1 x	15.7 x	2.2

* All estimates from Capital IQ

Debt calculations only included for entities with debt


NM - not meaningful

 Median
 0.1%
 2.3%
 0.2 x
 9.4 x
 0.2 x
 9.0 x
 2.1 x

 Mean
 0.1%
 4.0%
 0.6 x
 11.8 x
 0.6 x
 10.3 x
 2.4 x

 Min
 0.0%
 1.6%
 0.1 x
 8.8 x
 0.1 x
 8.5 x
 1.8 x

 Max
 0.3%
 13.1%
 2.4 x
 18.5 x
 2.1 x
 15.7 x
 4.1 x



CMO basket consists of the following: Albany Molecular Research, Inc. (NASDAQ:AMRI), Bachem (SWX:BANB), Balchem (NasdaqGS:BCPC), Cambrex (NYSE:CBM), Catalent (NYSE:CTLT), Jubilant (BSE:530019), DSM (ENXTAM:DSM), Lonza (SWX:LONN), Patheon (NYSE:PTHN), Siegfried (SWX:SFZN)

CRO basket consists of the following: Charles River (NYSE:CRL), ICON (NasdaqGS:ICLR), INC Research (NASDAQ:INCR), Medpace (NasdaqGS:MEDP), PAREXEL (NasdaqGS:PRXL), PRA Health Sciences (NasdaqGS:PRAH), Quintiles (NYSE:Q)

Distribution basket consists of: AmerisourceBergen (NYSE:ABC), Cardinal Health (NYSE:CAH), Celesio (DB:CLS1), McKesson (NYSE:MCK), Owens & Minor (NYSE:OMI), UDG Healthcare (LSE:UDG)

Source: S&P Capital IQ, May 25, 2017

- Below are the current TEV / EBITDA multiples for each sector:
 - CMO: 15.9x (31% above current S&P multiples)
 - CRO: 16.7x (37% above current S&P multiples)
 - Distribution: 9.6x (21% below current S&P multiples)
- Below are the average TEV / EBITDA multiples for each sector over the last 3 years:
 - CMO: 12.0x (12% above average S&P multiples)
 - CRO: 14.0x (29% above average S&P multiples)
 - Distribution: 12.0x (11% above average S&P multiples)
- Below are the % change in TEV / EBITDA multiples for each sector over the last 3 years:
 - CMO: +54% (up 31% in the last 12 months)
 - CRO: +39% (up 36% in the last 12 months)
 - Distribution: -30% (down 6% in the last 12 months)
 - S&P valuations are up 22% over the same period (up 9% in the last 12 months)